SCHEMBL15775852

SCHEMBL15775852

Cn1c(-c2ccccc2)cc2ccccc2c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.58
HPGD P15428 2/20 0.56
ALDH1A1 P00352 3/20 0.51
HSD17B10 Q99714 2/20 0.49
GAA P10253 1/20 0.49
PKM P14618 1/20 0.49
CASP1 P29466 1/20 0.49
GALK1 P51570 1/20 0.49
BLM P54132 1/20 0.49
CASP7 P55210 1/20 0.49
SAE1 Q9UBE0 1/20 0.49
UBA2 Q9UBT2 1/20 0.49
PDE4A P27815 1/20 0.48
PDE4B Q07343 1/20 0.48
PDE4C Q08493 1/20 0.48
PDE4D Q08499 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
NPC1 O15118 1/20 0.47
CASP3 P42574 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18156389 0.84 APP (0.44) KMT2AHPGDALDH1A1HSD17B10GAA
SCHEMBL16578792 0.84 L3MBTL1 (0.52) KMT2AHPGDALDH1A1HSD17B10GAA
SCHEMBL8657181 0.82 DPP4 (0.51) KMT2AHPGDALDH1A1HSD17B10CASP1
SCHEMBL9085554 0.80 KDM4E (0.49) KMT2AHPGDALDH1A1GAAPKM
SCHEMBL1035417 0.79 PGR (0.56) NPC1RAB9A
SCHEMBL6824613 0.79 KMT2A (0.51) KMT2AHPGDALDH1A1PKMPDE4A
SCHEMBL30160665 0.77 MAPK1 (0.53) KMT2AHPGDALDH1A1HSD17B10GAA
SCHEMBL28513461 0.77 MAPK1 (0.53) KMT2AHPGDALDH1A1HSD17B10GAA
SCHEMBL9194139 0.77 KDM4E (0.46) KMT2AHPGDALDH1A1NPC1RAB9A
SCHEMBL13180854 0.76 HSD17B10 (0.53) KMT2AHPGDALDH1A1HSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11286240-B2 Catalyst bound alpha radical and synthesis of OXO compounds using the same COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2022-03-29 US claimed
US-20210147364-A1 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2021-05-20 US claimed
US-11286240-B2 Catalyst bound alpha radical and synthesis of OXO compounds using the same COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2022-03-29 US disclosed
US-20210147364-A1 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2021-05-20 US disclosed
US-9758459-B2 Allosteric modulators of factor XIa as anticoagulant agents VIRGINIA COMMONWEALTH UNIVERSITY (US) 2017-09-12 US disclosed
US-9758459-B2 Allosteric modulators of factor XIa as anticoagulant agents VIRGINIA COMMONWEALTH UNIVERSITY (US) 2017-09-12 US disclosed
US-20160311842-A1 ALLOSTERIC MODULATORS OF FACTOR XIa AS ANTICOAGULANT AGENTS VIRGINIA COMMONWEALTH UNIVERSITY 2016-10-27 US disclosed
WO-2014087165-A1 TANKYRASE INHIBITORS UNIVERSITY OF BATH (GB) 2014-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11286240-B2 Catalyst bound alpha radical and synthesis of OXO compounds using the same CBR1, POR, CAT KMT2A 2616/4885HPGD 230/4885ALDH1A1 256/4885
US-20210147364-A1 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME CBR1, POR, CAT KMT2A 2513/4885HPGD 244/4885ALDH1A1 230/4885
US-20160311842-A1 ALLOSTERIC MODULATORS OF FACTOR XIa AS ANTICOAGULANT AGENTS TFPI, TFPI2, F10 KMT2A 3856/4885HPGD 2554/4885ALDH1A1 4470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.